This session brings together senior in-house patent litigators involved in some of the most influential recent pharma and biotech cases, to examine how life sciences litigation strategy is shifting and what in-house teams should be preparing for next.
- Review key cases and court decisions from the past year, and what they reveal about where pharma and biotech patent litigation is evolving.
- How PTAB procedural developments are changing risk assessment, sequencing, and settlement strategy.
- Review venue selection within the US and consider when long-arm litigation can create leverage.
Speaker(s):
Jason Murata
VP, IP
Alvotech
Petra Scamborova
Assistant General Counsel
Regeneron
Rob Rodrigues
Partner
RNA law
Eric Dittmann
Partner and Co-Chair, IP Practice
Paul Hastings
Time:
09:10am - 09:55am
Agenda Track No.:
Track 3
Session Type:
Panel
Force Inline Description:
0